Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Dec 18, 2025 • 18min
Toxicity Management of HER2+ Treatment Options in Upper GI Cancers – Drs. Geoffrey Ku & Shruti Patel
In this engaging discussion, Dr. Geoffrey Ku, a renowned medical oncologist at Memorial Sloan Kettering, and Dr. Shruti Patel from Stanford University share their expertise on managing treatment toxicities in HER2-positive upper GI cancers. They explore the complexities of frontline regimens, including trastuzumab and pembrolizumab, highlighting how to tackle common side effects like nausea and diarrhea. The duo also delves into cardiotoxicity and immune-related adverse events, offering practical recommendations for oncologists to enhance patient care.
Dec 15, 2025 • 15min
Current Treatment Landscape of Advanced Gastric/Esophageal/GEJ Adenocarcinoma – Dr. Rutika Mehta
Dr. Rutika Mehta, a GI medical oncologist at Weill Cornell, shares her expertise on advanced gastroesophageal cancers. She discusses the recent approval of durvalumab for resectable disease and the critical role of biomarker testing, particularly HER2, in treatment decisions. Insights into frontline therapies for HER2-positive patients and the significance of retesting HER2 upon disease progression are highlighted. Emerging treatments like TDXd and Zanidatamab also get attention, alongside considerations for managing side effects and treatment sequencing.
Dec 13, 2025 • 25min
Managing Toxicities of Antibody Drug Conjugates (ADCs) in Lung Cancer – Dr. Jacob Sands
Dr. Jacob Sands, a leading medical oncologist at Dana-Farber Cancer Institute, shares his expertise on antibody-drug conjugates (ADCs) and their impact on non-small cell lung cancer (NSCLC). He highlights the side effects of various ADCs like Trastuzumab deruxtecan, detailing risks such as interstitial lung disease and mucositis. Proactive strategies for managing toxicities are discussed, with insights on patient education and monitoring. This conversation is a goldmine for healthcare professionals seeking to enhance patient care and navigate the challenges of these innovative therapies.
Dec 11, 2025 • 22min
Managing Toxicities of PI3K & AKT Inhibitors in Breast Cancer – Drs. Emily Gallagher & Neil Iyengar
In this enlightening discussion, Dr. Emily Gallagher, an endocrinologist focused on metabolic complications of cancer therapy, joins Dr. Neil Iyengar, a breast medical oncologist specializing in targeted therapies. They dive into the nuances of PI3K and AKT inhibitors for hormone receptor-positive metastatic breast cancer. Listeners will learn about the management of common side effects like hyperglycemia and gastrointestinal issues, practical dosing strategies, and the critical role of patient education in ensuring effective treatment.
Dec 4, 2025 • 21min
Challenging Cases of Iron Abnormalities, Anemia or Iron Overload - Dr. Marina Beltrami
Dr. Marina Beltrami, a Hematologist from The Ohio State University specializing in non-malignant hematology, shares her insights on complex iron disorders. She discusses the crucial differences between IV and oral iron treatments for anemia in pregnancy. The conversation dives into managing elderly patients with mixed anemia causes, emphasizing comprehensive diagnostics including marrow biopsies and molecular tests. Dr. Beltrami also cautions against the risks of erythropoietin-stimulating agents and the careful approach needed for iron overload treatment.
Dec 4, 2025 • 22min
FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles
Join lymphoma expert Dr. Gilles Salles from Memorial Sloan Kettering as he discusses the recent FDA approval of Epcoritamab for relapsed follicular lymphoma. He reveals the promising EPCOR FL1 trial results, showcasing a striking progression-free survival benefit. Dr. Salles dives into the bispecific nature of Epcoritamab, how it targets CD20 and CD3, and shares insights on side effects like cytokine release syndrome. He also discusses the implications of minimal residual disease testing and where Epcoritamab fits into future treatment strategies.
Nov 30, 2025 • 23min
Challenging Cases in Second Line & Beyond Renal Cell Carcinoma (RCC) - Dr. David Braun
Dr. David Braun, a GU medical oncologist from Yale University, explores the complexities of second-line treatments for renal cell carcinoma. He delves into the different TKI options like cabozantinib and tivozanib, discussing their potency and side effects. The importance of assessing disease progression and biology is highlighted. Additionally, he reviews the risks associated with belzutifan and the management of common TKI-related adverse effects. The conversation emphasizes patient-centered care and decision-making in oncology.
Nov 26, 2025 • 17min
FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian
Join Dr. Yelena Y. Janjigian, a leading oncologist from Memorial Sloan Kettering and the pioneer behind the MATTERHORN study, as she unpacks groundbreaking insights into gastric and gastroesophageal cancer treatment. She shares the impressive three-year survival rate of 68.6% with Durvalumab combined with FLOT chemotherapy. The podcast also covers the study's design, the feasibility of immunotherapy, and its implications for managing patient side effects. Insights on extrapolating findings to esophageal adenocarcinoma further enrich this enlightening discussion.
Nov 24, 2025 • 24min
Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
Dr. Sara Tolaney, a breast cancer researcher at Dana-Farber, and Dr. Adam Brufsky from UPMC Hillman, dive into the latest advancements in CDK4/6 inhibitors. They discuss key trial updates, recommending abemaciclib for high-risk patients and exploring dosing strategies to manage side effects like diarrhea and neutropenia. Insights on tailoring treatment for metastatic cases and considering patient comorbidities highlight the importance of individualized care. Expect expert opinions on navigating the complexities of breast cancer therapeutics!
Nov 20, 2025 • 23min
Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks
Dr. Joshua Meeks, a urologist at Northwestern University, and Dr. Shilpa Gupta, a medical oncologist at Cleveland Clinic, dive into the intricacies of managing non-muscle invasive bladder cancer (NMIBC). They explore the definition of high-risk NMIBC and discuss groundbreaking clinical trials like CREST and POTOMAC, focusing on immunotherapy innovations. The duo emphasizes the need for a collaborative approach between urologists and oncologists, addresses the challenges of side effects from treatment, and highlights patient-centered discussions in this rapidly evolving field.
